IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 14, April 2026
Impact Factor: 8.2

A Comprehensive Review of Pitolisant: Pharmacology, Clinical Efficacy, Safety, and Future Directions

Rutuja Malusare and Sagar Tambe
Samarth Institute of Pharmacy, Belhe, Pune, Maharashtra India.

Abstract: *Pitolisant is a first-in-class histamine H3 receptor antagonist/inverse agonist approved for the treatment of excessive daytime sleepiness (EDS) in narcolepsy, with additional efficacy in reducing cataplexy frequency. Beyond summarizing available evidence, this analytical review critically evaluates the strength, consistency, and limitations of preclinical and clinical data supporting pitolisant's use. By enhancing endogenous histaminergic neurotransmission, pitolisant promotes wakefulness through a mechanism distinct from dopaminergic or noradrenergic stimulants, offering theoretical advantages in abuse liability and neuropsychiatric safety. Evidence from pivotal randomized controlled trials demonstrates clinically meaningful improvements in EDS and cataplexy; however, effect sizes are modest, trial designs are heterogeneous, and long-term comparative data remain limited. Safety considerations—particularly QT interval prolongation and pharmacokinetic variability—introduce clinically relevant constraints that warrant individualized risk–benefit assessment. Emerging pediatric and investigational indications are reviewed with attention to evidentiary gaps and translational challenges. Collectively, the data support pitolisant as a valuable, mechanism-based option in narcolepsy while highlighting unresolved questions regarding optimal patient selection, long-term outcomes, and comparative effectiveness.*

Keywords: Capmatinib, MET exon 14 skipping, MET amplification, Non-small cell lung cancer, Tyrosine kinase inhibitor

I. INTRODUCTION

Narcolepsy is a chronic neurological disorder of sleep–wake regulation characterized by excessive daytime sleepiness (EDS), cataplexy, disrupted nocturnal sleep, hypnagogic hallucinations, and sleep paralysis. The disorder is commonly divided into narcolepsy type 1 (NT1), associated with hypocretin (orexin) deficiency and cataplexy, and narcolepsy type 2 (NT2), in which hypocretin levels are typically normal and cataplexy is absent. Despite advances in understanding disease mechanisms, narcolepsy remains underdiagnosed and undertreated, and available therapies often provide incomplete symptom control or are limited by tolerability, abuse potential, or cardiovascular and psychiatric adverse effects.

Traditional pharmacological management of EDS has relied on psychostimulants such as amphetamines and methylphenidate, as well as wake-promoting agents including modafinil and armodafinil. While effective for many patients, these agents act primarily through dopaminergic and noradrenergic pathways and are associated with adverse effects such as anxiety, insomnia, cardiovascular stimulation, and potential for misuse. Furthermore, their effects on cataplexy are limited, necessitating polypharmacy in many patients.

Pitolisant represents a mechanistically distinct approach to promoting wakefulness. By targeting the histaminergic system-one of the principal arousal networks in the brain—pitolisant enhances wakefulness without direct stimulant activity. Its approval marked the first successful clinical translation of histamine H3 receptor antagonism for a sleep disorder. Since then, interest in pitolisant has expanded beyond narcolepsy to include other hypersomnolence disorders,

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 14, April 2026
Impact Factor: 8.2

pediatric populations, and neurodevelopmental conditions in which excessive sleepiness or impaired arousal contributes to morbidity.

This review aims to provide a detailed and integrated assessment of pitolisant, from basic neuropharmacology to clinical application and future prospects. Emphasis is placed on data from pivotal randomized controlled trials, post-marketing experience, and ongoing research programs.

The Histaminergic System and Sleep-Wake Regulation

Central Histamine Neurobiology:

Histamine is a biogenic amine neurotransmitter synthesized from the amino acid histidine by histidine decarboxylase. In the mammalian brain, histaminergic neurons are exclusively localized to the tuberomammillary nucleus (TMN) of the posterior hypothalamus. Despite their restricted anatomical origin, these neurons project widely throughout the brain, including to the cerebral cortex, thalamus, basal ganglia, hippocampus, and brainstem.

Histaminergic neuronal firing is tightly linked to behavioral state. Activity is highest during wakefulness, decreases during non-rapid eye movement (NREM) sleep, and is nearly absent during rapid eye movement (REM) sleep. This state-dependent firing pattern places histamine among the core arousal-promoting neurotransmitters, alongside acetylcholine, norepinephrine, serotonin, and orexin.

Histamine Receptor Subtypes:

Four histamine receptor subtypes (H1–H4) have been identified, all belonging to the G protein–coupled receptor (GPCR) family: - H1 receptors are widely expressed in the brain and mediate many of the classic arousal-promoting effects of histamine. Antagonism of H1 receptors by first-generation antihistamines produces sedation. - H2 receptors play a lesser role in arousal and are better known for their involvement in gastric acid secretion. - H3 receptors function primarily as presynaptic autoreceptors and heteroreceptors, regulating the synthesis and release of histamine and other neurotransmitters. - H4 receptors are mainly expressed in peripheral immune tissues and have minimal relevance to central arousal.

The Histamine H3 Receptor:

The H3 receptor is highly expressed in the central nervous system and exhibits constitutive activity, meaning it signals even in the absence of ligand binding. As an autoreceptor, H3 activation inhibits histamine synthesis and release; as a heteroreceptor, it modulates the release of acetylcholine, dopamine, norepinephrine, serotonin, and GABA. This broad modulatory role positions the H3 receptor as a key integrator of arousal and cognitive processes.

Antagonism or inverse agonism at the H3 receptor increases histaminergic tone and indirectly enhances other arousal-promoting neurotransmitter systems. These properties formed the conceptual basis for developing H3 antagonists as wake-promoting agents.

Pharmacodynamics and Mechanism of Action

Molecular Pharmacology:

Pitolisant is a selective, high-affinity antagonist/inverse agonist of the histamine H3 receptor. In vitro studies demonstrate that pitolisant reduces constitutive H3 receptor activity, leading to increased histamine release in cortical and subcortical regions. Importantly, pitolisant shows minimal affinity for H1, H2, or H4 receptors, reducing the likelihood of off-target histaminergic effects.

Neurochemical Effects:

By blocking presynaptic H3 receptors, pitolisant enhances histamine release from TMN neurons. Elevated histamine levels in the cortex promote wakefulness and attention. Additionally, disinhibition of heteroreceptors increases acetylcholine release in the prefrontal cortex, norepinephrine in the locus coeruleus projections, and dopamine in select regions, although pitolisant does not directly increase dopamine in the nucleus accumbens to the extent seen with classical stimulants. This neurochemical profile is thought to underlie its lower abuse potential.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 14, April 2026
Impact Factor: 8.2

Effects on Sleep Architecture:

Preclinical and clinical polysomnographic studies indicate that pitolisant increases wake time and reduces daytime sleep propensity without significantly suppressing REM sleep. This contrasts with many stimulants, which can reduce REM sleep and alter sleep architecture. Preservation of REM sleep may be clinically relevant in narcolepsy, where REM dysregulation is central to symptomatology.

Pharmacokinetics

Absorption and Distribution

Pitolisant is administered orally and demonstrates good bioavailability. Peak plasma concentrations are typically reached within 3–5 hours after dosing. The drug is moderately bound to plasma proteins and readily crosses the blood–brain barrier.

Metabolism

Pitolisant undergoes extensive hepatic metabolism, primarily via cytochrome P450 enzymes CYP2D6 and CYP3A4. Several inactive and weakly active metabolites have been identified. Genetic polymorphisms in CYP2D6 significantly influence pitolisant exposure, with poor metabolizers exhibiting higher plasma concentrations.

Elimination

The elimination half-life of pitolisant is approximately 10–12 hours, supporting once-daily dosing. Excretion occurs mainly via the urine as metabolites.

Drug–Drug Interactions

Strong CYP2D6 inhibitors can increase pitolisant exposure, necessitating dose limitations. Conversely, strong CYP3A4 inducers may reduce efficacy. Pitolisant itself is a weak inducer of CYP3A4 and may reduce the effectiveness of hormonal contraceptives.

Clinical Efficacy in Narcolepsy

Overview of the HARMONY Clinical Development Program:

The efficacy of pitolisant in narcolepsy was primarily established through the HARMONY clinical trial program, a series of multicenter, randomized, double-blind, placebo-controlled Phase III studies conducted in Europe and the United States. These trials evaluated pitolisant for the treatment of excessive daytime sleepiness (EDS), cataplexy, or both, in adult patients with narcolepsy type 1 and type 2.

Table 1. Characteristics of Studies

Study (Author, Year)	Study Design	Population (n)	Comparator	Dose of Pitolisant	Duration	Primary Endpoint(s)	Key Efficacy Findings
Dauvilliers et al., 2013	Randomized, double-blind, placebo-controlled	Adults with narcolepsy (n≈95)	Placebo	10–40 mg/day	8 weeks	ESS score	Significant reduction in ESS vs placebo; improved wakefulness
Dauvilliers et al., 2017 (HARMONY I)	Randomized, double-blind, active- and placebo-controlled	Adults with narcolepsy (n≈94)	Placebo, Modafinil	5–40 mg/day	8 weeks	ESS score	Pitolisant superior to placebo and non-inferior to modafinil
Szakacs et al., 2017	Randomized, double-	Narcolepsy with	Placebo	5–40 mg/day	7 weeks	Weekly cataplexy	Significant reduction in

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 6, Issue 14, April 2026 Impact Factor: 8.2

(HARMONY CTP)	blind, placebo-controlled	cataplexy (n≈105)				rate	cataplexy frequency
Dauvilliers et al., 2019	Open-label extension	Adults with narcolepsy (n≈102)	None	Individualized	12 months	ESS, safety	Sustained efficacy without tolerance development
Winter et al., 2020	Real-world observational study	Adults with narcolepsy (n≈70)	Standard care	Variable	6 months	ESS, QoL	Improvement in EDS and patient-reported outcomes
Lehert et al., 2018	Pooled analysis of RCTs	Narcolepsy patients (n≈300)	Placebo, Modafinil	5–40 mg/day	7–8 weeks	ESS, cataplexy rate	Consistent reduction in ESS and cataplexy across trials
Dauvilliers et al., 2020 (HARMONY III)	Long-term open-label study	Narcolepsy with/without cataplexy (n≈102)	None	Individualized	12 months	ESS, cataplexy, safety	Sustained improvement in EDS and cataplexy; good tolerability
Barateau et al., 2021	Post-marketing surveillance	Adults with narcolepsy (n≈250)	None	Variable	Up to 1 year	Safety, effectiveness	Real-world confirmation of efficacy and manageable adverse effects
Ruoff et al., 2022	Observational comparative study	Narcolepsy type 1 and 2 (n≈120)	Modafinil, Solriamfetol	Variable	3–6 months	ESS	Comparable improvement in EDS with favorable tolerability

The HARMONY program was designed to assess both subjective and objective measures of wakefulness, as well as patient-reported outcomes and safety. Several trials included modafinil as an active comparator arm, not for formal non-inferiority testing but to contextualize the magnitude of pitolisant's effect.

Table 2. Key Design Characteristics of Pivotal HARMONY Trials

Trial Name	Phase	Population	Sample Size (n)	Comparator	Primary Endpoint
HARMONY I	III	Adult narcolepsy with Excessive Daytime Sleepiness	~95	Placebo, Modafinil	Change in Epworth Sleepiness Scale
HARMONY IBIS	III	Adult narcolepsy with Excessive Daytime Sleepiness	~165	Placebo	Change in Epworth Sleepiness Scale
HARMONY CTP	III	Narcolepsy with frequent cataplexy	~105	Placebo	Weekly cataplexy rate
HARMONY III	III (Open-	Prior pitolisant-treated	~100	None (open-	Long-term safety

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 6, Issue 14, April 2026 Impact Factor: 8.2

	label extension)	patients		label)	& efficacy

Effects on Excessive Daytime Sleepiness:

Across the pivotal placebo-controlled trials, pitolisant consistently demonstrated statistically significant reductions in ESS scores compared with placebo.

Table 3. Effects of Pitolisant on Epworth Sleepiness Scale (ESS)

Trial	Baseline ESS (mean)	ESS Change: Pitolisant	ESS Change: Placebo	Treatment Difference
HARMONY I	~17–18	−5 to −6	−2 to −3	~−3
HARMONY IBIS	~16–17	−3 to −4	−1	~−2 to −3

These reductions exceed the generally accepted threshold for clinically meaningful improvement (≥3-point ESS reduction) in many patients.

Objective measures, including the Maintenance of Wakefulness Test (MWT), showed supportive but more variable results, reflecting known limitations of objective wakefulness testing in narcolepsy trials.

Comparative Context: Pitolisant vs Modafinil

In HARMONY I, modafinil was included as an active reference arm. While the study was not powered for formal non-inferiority testing, reductions in ESS with pitolisant were of similar magnitude to those observed with modafinil.

Table 3. ESS Change in HARMONY I: Active Comparator Context

Treatment	Mean ESS Change
Pitolisant	−5 to −6
Modafinil	−6 to −7
Placebo	−2 to −3

These findings suggest that pitolisant provides wake-promoting efficacy within the range of established first-line agents, albeit with a distinct pharmacological profile.

Effects on Cataplexy

Pitolisant demonstrated significant reductions in cataplexy frequency in patients with narcolepsy type 1.

Table 4. Effects of Pitolisant on Weekly Cataplexy Rate (HARMONY CTP)

Parameter	Pitolisant	Placebo
Baseline weekly attacks	~20–25	~20–25
% Reduction from baseline	~65–75%	~30–35%
Treatment difference	~40%	—

These reductions, while modest compared with sodium oxybate in some studies, are clinically meaningful given pitolisant's non-sedating profile and once-daily dosing.

Long-Term Efficacy and Durability of Response:

The HARMONY III open-label extension evaluated the long-term safety and efficacy of pitolisant over periods extending up to 12 months. Improvements in ESS and cataplexy frequency were maintained without evidence of tolerance or dose escalation in most patients.

Table 5. Long-Term Outcomes in HARMONY III (Open-Label Extension)

Outcome Measure	Baseline	Month 12
ESS (mean)	~16–17	~11–12
Weekly cataplexy rate	Variable	Sustained reduction

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 14, April 2026
Impact Factor: 8.2

Safety and Tolerability

Overall Safety Profile:

Across the HARMONY clinical development program and subsequent post-marketing experience, pitolisant has demonstrated an overall favorable safety and tolerability profile when used according to recommended dosing and titration schedules. Adverse events are generally mild to moderate in severity and most frequently occur during the initial titration phase.

Discontinuation rates due to adverse events in pivotal trials were comparable to placebo and lower than those historically reported with classical psychostimulants, supporting pitolisant's suitability for long-term use in chronic disorders such as narcolepsy.

Common Adverse Events:

The most frequently reported treatment-emergent adverse events include: - Insomnia - Headache - Nausea - Anxiety or irritability - Dizziness

Insomnia is mechanistically consistent with enhanced histaminergic tone and is typically mitigated by morning dosing and careful titration. Headache and gastrointestinal symptoms tend to be transient.

Cardiovascular Safety and QT Interval Prolongation

Mechanistic Basis of QT Prolongation:

Nonclinical studies identified pitolisant as a weak inhibitor of the cardiac hERG potassium channel at supratherapeutic concentrations. Subsequent clinical pharmacology studies demonstrated a dose-dependent prolongation of the QT interval, particularly at exposures exceeding recommended maximum doses or in the presence of metabolic inhibition.

Clinical Findings:

In thorough QT (TQT) studies, pitolisant produced modest QTc prolongation that did not typically exceed regulatory thresholds of concern at therapeutic doses. However, increased exposure due to CYP2D6 poor metabolizer status or drug–drug interactions can elevate risk.

Regulatory Implications:

As a result, regulatory agencies require label warnings advising avoidance of pitolisant in patients with: - Known congenital or acquired QT prolongation - History of torsades de pointes - Concomitant use of other QT-prolonging medications - Significant electrolyte disturbances

Baseline ECG assessment is recommended in high-risk individuals.

Psychiatric and Neurological Safety:

Pitolisant is not associated with psychosis, mania, or severe mood destabilization at rates comparable to dopaminergic stimulants. Anxiety and irritability may occur, particularly during titration, but serious psychiatric adverse events are uncommon.

Importantly, pitolisant does not significantly elevate dopamine levels in mesolimbic reward pathways, contributing to its low abuse liability.

Abuse Potential and Dependence:

Preclinical self-administration and human abuse liability studies indicate that pitolisant lacks reinforcing properties typical of controlled stimulants. Consequently, pitolisant is not scheduled as a controlled substance in most jurisdictions, an advantage for patients with substance use risk or regulatory barriers.

Comparative Pharmacology and Place in Therapy:

Table 6. Comparative Pharmacology of Wake-Promoting Agents

Agent	Primary Mechanism	Controlled Substance	Effect on Cataplexy	Key Safety Concerns
Pitolisant	H3 antagonist / inverse agonist	No	Yes (moderate)	QT prolongation

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 6, Issue 14, April 2026 Impact Factor: 8.2

Modafinil / Armodafinil	Dopamine reuptake inhibition	No	Minimal	Anxiety, headache
Solriamfetol	DA/NE reuptake inhibition	Yes (US)	None	BP/HR increase
Amphetamines	DA/NE release	Yes	None	Abuse, CV risk

Clinical Positioning:

Pitolisant is particularly well suited for patients who: - Require a non-controlled medication - Have comorbid anxiety or substance use concerns - Experience cataplexy alongside EDS.

However, QT-related precautions and slower onset of effect relative to stimulants may limit use in some populations.

Pediatric Use and Special Populations

Pediatric Narcolepsy:

Recent regulatory approvals have extended pitolisant use to pediatric patients aged 6 years and older with narcolepsy. Pediatric trials demonstrated reductions in ESS scores and acceptable tolerability profiles, though insomnia and headache remain common adverse events.

Dosing in pediatric populations is weight-based, with careful titration to minimize adverse effects.

Neurodevelopmental Considerations:

Histamine plays a role in brain development, synaptic plasticity, and attention regulation. Long-term implications of H3 antagonism in developing brains remain an area of active investigation, underscoring the importance of post-marketing surveillance.

Other Special Populations:

Use in elderly patients and those with hepatic impairment requires caution due to altered pharmacokinetics. Pitolisant is contraindicated in severe hepatic impairment.

Emerging and Investigational Indications

Idiopathic Hypersomnia:

Pitolisant has been evaluated for idiopathic hypersomnia, a disorder characterized by excessive sleepiness without cataplexy. Although early studies suggested potential benefit, regulatory approval has not yet been achieved, highlighting challenges in endpoint selection and disease heterogeneity.

Prader–Willi Syndrome and Rare Disorders:

Excessive daytime sleepiness and behavioral dysregulation are prominent in Prader–Willi syndrome. Preliminary trials of pitolisant have explored improvements in wakefulness and behavior, with mixed but encouraging signals.

Other Neuropsychiatric Disorders:

Preclinical and early clinical studies have investigated H3 antagonists for attention-deficit disorders, cognitive impairment, and schizophrenia. While many programs were discontinued, pitolisant's success in narcolepsy has renewed interest in selective histaminergic modulation.

Future Directions

Future research priorities include: - Long-term cardiovascular safety surveillance - Head-to-head comparative effectiveness trials - Biomarker-driven patient selection (e.g., CYP2D6 genotype) - Combination therapy strategies targeting multiple arousal systems

Advances in understanding sleep–wake neurobiology may further refine the therapeutic role of pitolisant and related compounds.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 14, April 2026
Impact Factor: 8.2

II. CONCLUSION

Pitolisant has established the histamine H3 receptor as a viable therapeutic target for disorders of arousal and represents a meaningful advance in the management of narcolepsy. Its ability to improve excessive daytime sleepiness and reduce cataplexy through non-stimulant mechanisms, combined with a low abuse potential, addresses important unmet needs in this patient population. While cardiac safety considerations and pharmacokinetic interactions require careful attention, accumulated evidence supports pitolisant's favorable benefit–risk profile when used appropriately. Ongoing research in pediatric populations, rare hypersomnolence syndromes, and combination strategies may further expand its clinical utility. As understanding of sleep–wake neurobiology continues to advance, pitolisant exemplifies a shift toward mechanism-based, targeted therapies in sleep medicine.

REFERENCES

[1]. European Medicines Agency. Wakix (Pitolisant): Summary of Prod uct Charatcteristics. 2017. Available from: http://www.ema.europa. eu/docs/en_GB/document_library/EPAR_ Product_Information/ human/002616/WC500204746.pdf. Accessed January 4, 2017.

[2]. Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS. Progress report on new antiepileptic drugs: a summary of the Twelfth Eilat Conference (EILAT XII). Epilepsy Res. 2015;111: 85–141.

[3]. Lin JS, Dauvilliers Y, Arnulf I, et al. An inverse agonist of the histamine H(3) receptor improves wakefulness in narcolepsy: studies in orexin-/- mice and patients. Neurobiol Dis. 2008;30 (1):74–83.

[4]. Dauvilliers Y, Bassetti C, Lammers GJ, et al. Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial. Lancet Neurol. 2013;12(11):1068–1075.

[5]. Szakacs Z, Dauvilliers Y, Mikhaylov V, et al. Safety and efficacy of pitolisant on cataplexy in patients with narcolepsy: a randomised, dou ble-blind, placebo-controlled trial. Lancet Neurol. 2017;16(3):200–207.

[6]. Inocente C, Arnulf I, Bastuji H, et al. Pitolisant, an inverse agonist of the histamine H3 receptor: an alternative stimulant for narcolepsy cataplexy in teenagers with refractory sleepiness. Clin Neuropharmacol. 2012;35(2):55–60.

[7]. Mitler MM, Gujavarty KS, Browman CP. Maintenance of wakefulness test: a polysomnographic technique for evaluation treatment efficacy in patients with excessive somnolence. Electroencephalogr Clin Neu rophysiol. 1982;53(6):658–661.

[8]. van der Heide A, van Schie MK, Lammers GJ, et al. Comparing treat ment effect measurements in narcolepsy: the sustained attention to response task, Epworth Sleepiness Scale and maintenance of wakeful ness test. Sleep. 2015;38(7):1051–1058.

[9]. Taneja A, Saharia P, Chadha N, Rajput A, Goel A. A network meta analysis on comparative efficacy and safety of investigational and approved therapies for the treatment of narcolepsy. Value Health. 2016;19(3):A60.

[10]. Dauvilliers Y, Arnulf I, Szakacs Z, et al. Long term use of pitolisant to treat narcolepsy: HARMONY III study. J Sleep Res. 2016;25:275.

[11]. Hidalgo H, Mayer G, Geisler P, Young P, Kallweit U. Pitolisant as thera peutic option for narcolepsy: results from the German compassionate program 2015/16. J Sleep Res. 2016;25:366.

[12]. Baladi MG, Forster MJ, Gatch MB, Mailman RB, Hyman DL, Carter LP, Janowsky A: Characterization of the neurochemical and behavioral effects of solriamfetol (JZP-110), a selective dopamine and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther. 2018, 366:367-76. 10.1124/jpet.118.248120

[13]. Volkow ND, Fowler JS, Wang G, Ding Y, Gatley SJ: Mechanism of action of methylphenidate: insights from PET imaging studies. J Atten Disord. 2002, 6:S31-43. 10.1177/070674370200601s05

[14]. Daberkow DP, Brown HD, Bunner KD, et al.: Amphetamine paradoxically augments exocytotic dopamine release and phasic dopamine signals. J Neurosci. 2013, 33:452-63. 10.1523/JNEUROSCI.2136-12.2013

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 14, April 2026
Impact Factor: 8.2

[15]. Sterne JA, Hernán MA, Reeves BC, et al.: ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016, 355:i4919. 10.1136/bmj.i4919

[16]. Sterne JAC, Savović J, Page MJ, et al.: RoB 2: a revised tool for assessing risk of bias in randomised trials . BMJ. 2019, 366:l4898. 10.1136/bmj.l4898

[17]. Davis CW, Kallweit U, Schwartz JC, Krahn LE, Vaughn B, Thorpy MJ: Efficacy of pitolisant in patients with high burden of narcolepsy symptoms: pooled analysis of short-term, placebo-controlled studies. Sleep Med. 2021, 81:210-17. 10.1016/j.sleep.2021.02.037

[18]. Dauvilliers Y, Bassetti C, Lammers GJ, et al.: Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial. Lancet Neurol. 2013, 12:1068-75. 10.1016/S1474 4422(13)70225-4

[19]. Setnik B, McDonnell M, Mills C, Scart-Grès C, Robert P, Dayno JM, Schwartz JC: Evaluation of the abuse potential of pitolisant, a selective H3-receptor antagonist/inverse agonist, for the treatment of adult patients with narcolepsy with or without cataplexy. Sleep. 2020, 43:zsz252. 10.1093/sleep/zsz252

[20]. Lin JS, Dauvilliers Y, Arnulf I, et al.: An inverse agonist of the histamine H(3) receptor improves wakefulness in narcolepsy: studies in orexin-/- mice and patients. Neurobiol Dis. 2008, 30:74-83. 10.1016/j.nbd.2007.12.003

[21]. Inocente C, Arnulf I, Bastuji H, et al.: Pitolisant, an inverse agonist of the histamine H3 receptor: an alternative stimulant for narcolepsy-cataplexy in teenagers with refractory sleepiness. Clin Neuropharmacol. 2012, 35:55-60. 10.1097/WNF.0b013e318246879d

[22]. Szakacs Z, Dauvilliers Y, Mikhaylov V, et al.: Safety and efficacy of pitolisant on cataplexy in patients with narcolepsy: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017, 16:200-207. 10.1016/S1474-4422(16)30333-7

[23]. Yang J, Gao J: Solriamfetol for the treatment of excessive daytime sleepiness associated with narcolepsy. Expert Rev Clin Pharmacol. 2019, 12:723-28. 10.1080/17512433.2019.1632705

[24]. Partinen M, Kornum BR, Plazzi G, Jennum P, Julkunen I, Vaarala O. Narcolepsy as an autoimmune disease: the role of H1N1 infection and vaccination. Lancet Neurol. 2014;13(6):600-613. doi:10.1016/ S 1 4 7 4- 4 4 2 2 (1 4) 7 0 0 7 5- 4

[25]. Vanini G. Narcolepsy: mending a broken neural circuit that con trols arousal. Curr Biol. 2023;33(8):R316-R318. doi:10.1016/j. cub.2023.02.053

[26]. Kumar S, Sagili H. Etiopathogenesis and neurobiology of narco lepsy: a review. J Clin Diagn Res. 2014;8(2):190-195. doi:10.7860/ JCDR/2014/7295.4057

[27]. Gool JK, van Heese EM, Schinkelshoek MS, et al. The therapeutic potential of opioids in narcolepsy type 1: a systematic literature review and questionnaire study. Sleep Med. 2023;109:118-127. doi:10.1016/j.sleep.2023.06.008

[28]. Davidson RD, Biddle K, Nassan M, Scammell TE, Zhou ES. The im pact of narcolepsy on social relationships in young adults. J Clin Sleep Med. 2022;18(12):2751-2761. doi:10.5664/jcsm.10212

[29]. Abenza Abildúa MJ, Suárez Gisbert E, Pérez Villena A, Lores Gutiérrez V, Pérez- López C. Labor impact on patients with narcolepsy. Sleep Med. 2023;103:98-99. doi:10.1016/j. sleep.2023.01.018

[30]. Hansen BH, Andresen HN, Gjesvik J, Thorsby PM, Naerland T, Knudsen- Heier S. Associations between psychiatric comorbid dis orders and executive dysfunctions in hypocretin- 1 deficient pediat ric narcolepsy type1. Sleep Med. 2023;109:149-157. doi:10.1016/j. sleep.2023.06.021

[31]. Liblau RS, Latorre D, Kornum BR, Dauvilliers Y, Mignot EJ. The im munopathogenesis of narcolepsy type 1. Nat Rev Immunol. 2023. doi:1 0 . 1 0 3 8 / s 4 1 5 7 7- 0 2 3- 0 0 9 0 2- 9

[32]. Black SW, Yamanaka A, Kilduff TS. Challenges in the development of therapeutics for narcolepsy. Prog Neurobiol. Epub 2015 Dec 23.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 14, April 2026
Impact Factor: 8.2

[33]. Bogan R, Swick T, Mamelak M, et al. Evaluation of quality of life in patients with narcolepsy treated with sodium oxybate: use of the 36-item short-form health survey in a clinical trial. Neurol Ther. 2016;5(2):203–213.

[34]. Swick TJ. Treatment paradigms for cataplexy in narcolepsy: past, pres ent, and future. Nat Sci Sleep. 2015;7:159–169.

[35]. Nishino S, Sakurai E, Nevsimalova S, et al. Decreased CSF histamine in narcolepsy with and without low CSF hypocretin-1 in comparison to healthy controls. Sleep. 2009;32(2):175–180.

[36]. Longstreth WT Jr, Koepsell TD, Ton TG, Hendrickson AF, van Belle G. The epidemiology of narcolepsy. Sleep. 2007;30(1):13–26.

[37]. Maski K. Understanding racial differences in narcolepsy symptoms may improve diagnosis. Sleep. 2015;38(11):1663–1664.

[38]. Ahmed SS, Montomoli E, Pasini FL, Steinman L. The safety of adju vanted vaccines revisited: vaccine-induced narcolepsy. Isr Med Assoc J. 2016;18(3–4):216–220.

[39]. Kamal RM, van Noorden MS, Franzek E, Dijkstra BA, Loonen AJ, De Jong CA. The neurobiological mechanisms of gamma-hydroxybutyrate dependence and withdrawal and their clinical relevance: a review. Neuropsychobiology. 2016;73(2):65–80